Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

66.58
-0.3700-0.55%
Post-market: 66.47-0.1103-0.17%19:55 EDT
Volume:5.54M
Turnover:368.73M
Market Cap:135.54B
PE:14.66
High:66.84
Open:66.77
Low:66.19
Close:66.95
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.82
T/O Rate:0.27%
Dividend:2.51
Dividend Rate:3.77%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:6.07
PE(LYR):19.24

Loading ...

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 20

Movement Alert|Bristol-Myers Squibb Rises 3.11% in Regular Trading, Zenbexus Gains FDA Accelerated Approval as Pharma Sector Rallies

Market Focus
·
Aug 19

Hengrui Pharma FY26 H1 Profit Attributable to Owners Rises 0.3% to RMB 4.47 Billion; Revenue Falls 1.9% to RMB 15.46 Billion

Reuters
·
Aug 19

The Key to Pharma M&A: Never Shopping Hungry - Heard on the Street

Dow Jones
·
Aug 19

Lytix Biopharma Names Timothy Herpin Chief Business Officer

Reuters
·
Aug 18

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 18

AstraZeneca Suffers Another Setback as it Halts Volrustomig Lung Cancer Trial

Reuters
·
Aug 17

How First CELMoD MRD-Based Approval in Myeloma At Bristol Myers Squibb (BMY) Has Changed Its Investment Story

Simply Wall St.
·
Aug 15

Mubadala Investment Co Pjsc Reports Share Stake in Ford Motor, Phillips 66, Dissolves in Apple

Reuters
·
Aug 14

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Citi Remains a Hold on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Aug 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (CRBU), Bristol-Myers Squibb (BMY) and Schrodinger (SDGR)

TIPRANKS
·
Aug 14

Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data

TIPRANKS
·
Aug 14

Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise

Reuters
·
Aug 14

FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus for Relapsed Multiple Myeloma Combo Use

Reuters
·
Aug 14

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First Celmod Therapy Zenbexus™, in Combination with Daratumumab and Hyaluronidase-Fihj and Dexamethasone (Zdd) for Patients with Multiple Myeloma, as Early as First Relapse

THOMSON REUTERS
·
Aug 14

Bristol-Myers Squibb - Zenbexus Available Only Through Restricted Zenbexus Rems Program

THOMSON REUTERS
·
Aug 14

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

US FDA Approves Bristol Myers' Blood Cancer Treatment

Reuters
·
Aug 14

FDA Grants Accelerated Approval to Iberdomide with Daratumumab and Hyaluronidase-Fihj and Dexamethasone for Multiple Myeloma

THOMSON REUTERS
·
Aug 14